Business, Policy & Funding
Breaking news on precision medicine business, policy & funding.
Axovia Therapeutics, Viralgen Partner on Bardet-Biedl Syndrome Gene Therapy
The companies will focus on advancing AXV-101, with which they hope to treat retinal dystrophy by targeting mutations in the BBS1 gene.
Doctors and patient advocates supporting pretreatment testing at times challenged FDA and other experts who aren't swayed by available evidence.
J&J Reports Strong Uptake of Carvykti and Rybrevant in Q4
The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.
NICE Recommends NHS England Provide AstraZeneca's Tagrisso for Adjuvant EGFR-Mutated NSCLC
The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.
Cartesian Therapeutics Kicking off Phase III Cell Therapy Trial in Myasthenia Gravis
The company also continues to study Descartes-08 in other autoimmune diseases and has plans for a basket trial in pediatric patients.